ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2008
Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.British journal of clinical pharmacology · 2018Pooled it
- Impact of safety-related regulatory action on clinical practice: a systematic review.Drug safety · 2012Pooled it
- Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.Drug safety · 2010Pooled it
- Non-adherence to antidementia medications and associated factors: a study of Spanish population-based registry data.Frontiers in pharmacology · 2024Article
- Trends in the use of psychotropics in older people with dementia: interrupted time series of Finnish clinical guidelines of behavioural and psychological symptoms of dementia.Age and ageing · 2023Article
- Animal Models of Psychosis in Alzheimer Disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2020Review
- Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines.Pharmacy (Basel, Switzerland) · 2019Article
- The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?Drug safety · 2019Review
- Public reporting of antipsychotic prescribing in nursing homes: population-based interrupted time series analyses.BMJ quality & safety · 2019Article
- Nonpharmacological Management of Behavioral and Psychological Symptoms of Dementia: What Works, in What Circumstances, and Why?Innovation in aging · 2018Article
- Potentially inappropriate prescriptions for elderly people taking antidepressant: comparative tools.BMC geriatrics · 2017Article
- The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin.Drugs - real world outcomes · 2017Article
- Article
- Detecting and Managing Neuropsychiatric Symptoms in Dementia.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Article
- Antipsychotic Use in Dementia.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Review
- Article
- Article
- Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort Study.Drugs & aging · 2016Article
- Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study.SAGE open medicine · 2016Article
- A retrospective, longitudinal study of factors associated with new antipsychotic medication use among recently admitted long-term care residents.BMC geriatrics · 2015Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThree warnings of serious adverse events associated with the use of atypical antipsychotic drugs among elderly patients with dementia were sent to health care professionals in Canada. We assessed the impact of these warnings on prescription rates of antipsychotic drugs in this patient population.
methodsWe used prescription drug claims data from Ontario to calculate prescription rates of atypical and conventional antipsychotic drugs among elderly patients with dementia from May 1, 2000, to Feb. 28, 2007. We performed a time-series analysis to estimate the effect of each warning on rates of antipsychotic drug use.
resultsBefore the first warning, growth in the use of atypical antipsychotics was responsible for an increasing rate of overall antipsychotic use. Each warning was associated with a small relative decrease in the predicted growth in the use of atypical antipsychotic drugs: a 5.0% decrease after the first warning, 4.9% after the second and 3.2% after the third (each p < 0.05). The overall prescription rate of antipsychotic drugs among patients with dementia increased by 20%, from 1512 per 100 000 elderly patients in September 2002, the month before the first warning, to 1813 per 100 000 in February 2007, 20 months after the last warning.
interpretationAlthough the warnings slowed the growth in the use of atypical antipsychotic drugs among patients with dementia, they did not reduce the overall prescription rate of these potentially dangerous drugs. More effective interventions are necessary to improve postmarket drug safety in vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.